Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
27 04 2021
27 04 2021
Historique:
received:
22
09
2020
accepted:
22
02
2021
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
1
6
2021
Statut:
ppublish
Résumé
Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem cell malignancies that can phenotypically resemble other hematologic disorders. Thus, tools that may add to current diagnostic practices could aid in disease discrimination. Constitutive innate immune activation is a pathogenetic driver of ineffective hematopoiesis in MDS through Nod-like receptor protein 3 (NLRP3)-inflammasome-induced pyroptotic cell death. Oxidized mitochondrial DNA (ox-mtDNA) is released upon cytolysis, acts as a danger signal, and triggers inflammasome oligomerization via DNA sensors. By using immortalized bone marrow cells from murine models of common MDS somatic gene mutations and MDS primary samples, we demonstrate that ox-mtDNA is released upon pyroptosis. ox-mtDNA was significantly increased in MDS peripheral blood (PB) plasma compared with the plasma of healthy donors, and it was significantly higher in lower-risk MDS vs higher-risk MDS, consistent with the greater pyroptotic cell fraction in lower-risk patients. Furthermore, ox-mtDNA was significantly higher in MDS PB plasma compared with all other hematologic malignancies studied, with the exception of chronic lymphocytic leukemia (CLL). Receiver operating characteristic/area under the curve (ROC/AUC) analysis demonstrated that ox-mtDNA is a sensitive and specific biomarker for patients with MDS compared with healthy donors (AUC, 0.964), other hematologic malignancies excluding CLL (AUC, 0.893), and reactive conditions (AUC, 0.940). ox-mtDNA positively and significantly correlated with levels of known alarmins S100A9, S100A8, and apoptosis-associated speck-like protein containing caspase recruitment domain (CARD) specks, which provide an index of medullary pyroptosis. Collectively, these data indicate that quantifiable ox-mtDNA released into the extracellular space upon inflammasome activation serves as a biomarker for MDS and the magnitude of pyroptotic cell death.
Identifiants
pubmed: 33890980
pii: S2473-9529(21)00278-0
doi: 10.1182/bloodadvances.2020003475
pmc: PMC8095151
doi:
Substances chimiques
Biomarkers
0
DNA, Mitochondrial
0
Inflammasomes
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2216-2228Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Informations de copyright
© 2021 by The American Society of Hematology.
Références
Front Immunol. 2018 Nov 20;9:2633
pubmed: 30515154
Lancet Haematol. 2018 Sep;5(9):e393-e402
pubmed: 30072146
Blood. 2019 Mar 7;133(10):1086-1095
pubmed: 30670443
Immunity. 2020 Mar 17;52(3):475-486.e5
pubmed: 32164878
Blood. 2014 Apr 24;123(17):2663-72
pubmed: 24553174
J Clin Invest. 2013 Nov;123(11):4595-611
pubmed: 24216507
Science. 1989 Oct 27;246(4929):500-3
pubmed: 2814477
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
Biomed Res Int. 2014;2014:686392
pubmed: 25054143
Front Immunol. 2018 May 04;9:832
pubmed: 29780380
Immunol Rev. 2007 Dec;220:60-81
pubmed: 17979840
J Leukoc Biol. 2004 Jun;75(6):995-1000
pubmed: 14982943
Oncotarget. 2017 Jul 5;8(43):73483-73500
pubmed: 29088721
Nature. 2018 Aug;560(7717):198-203
pubmed: 30046112
Cancer Cell. 2015 May 11;27(5):617-30
pubmed: 25965569
Eur J Immunol. 2014 May;44(5):1552-62
pubmed: 24470107
Am J Clin Pathol. 2007 Aug;128(2):323-32
pubmed: 17638669
Mol Cell. 2019 May 16;74(4):801-815.e6
pubmed: 30952515
Cancer Discov. 2019 Jun;9(6):778-795
pubmed: 30944118
Immunology. 2004 Oct;113(2):212-23
pubmed: 15379982
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):97-104
pubmed: 31808900
Oncol Rev. 2018 Dec 07;12(2):397
pubmed: 30607219
Cell Death Differ. 2007 Sep;14(9):1590-604
pubmed: 17599095
Nat Biotechnol. 2014 Sep;32(9):941-6
pubmed: 24952903
Blood Adv. 2019 Dec 23;3(24):4271-4279
pubmed: 31869414
J Exp Med. 2016 Sep 19;213(10):2113-28
pubmed: 27573815
Arthritis Res Ther. 2003;5(5):R234-40
pubmed: 12932286
Blood. 2018 Aug 9;132(6):608-621
pubmed: 29903888
Nat Med. 2007 Sep;13(9):1042-9
pubmed: 17767165
J Biol Chem. 1994 May 27;269(21):15195-203
pubmed: 8195155
Immunity. 2012 Mar 23;36(3):401-14
pubmed: 22342844
Nucleic Acids Res. 1978 Jun;5(6):2197-210
pubmed: 673850
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15514-9
pubmed: 25313054
Diabetes. 2013 Jan;62(1):194-204
pubmed: 23086037
Nature. 2015 Oct 29;526(7575):660-5
pubmed: 26375003
Pediatr Res. 2012 Jun;71(6):626-32
pubmed: 22337228
PLoS One. 2013 Aug 19;8(8):e72138
pubmed: 23977231
Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14566-71
pubmed: 21873190
Immunol Res. 2013 Mar;55(1-3):10-21
pubmed: 22941560
Immunity. 2016 Apr 19;44(4):833-46
pubmed: 27037191
Blood. 2016 Dec 22;128(25):2960-2975
pubmed: 27737891
Blood. 2018 Apr 26;131(17):1942-1954
pubmed: 29467184
Nature. 2010 Mar 4;464(7285):104-7
pubmed: 20203610
Nat Methods. 2006 Apr;3(4):287-93
pubmed: 16554834
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582